gabexate has been researched along with Hepatitis C in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ito, N | 1 |
Kawata, S | 1 |
Tamura, S | 1 |
Kiso, S | 1 |
Tsushima, H | 1 |
Maeda, Y | 1 |
Yamasaki, E | 1 |
Igura, T | 1 |
Matsuzawa, Y | 1 |
1 other study available for gabexate and Hepatitis C
Article | Year |
---|---|
Induction of interleukin-6 by interferon alfa and its abrogation by a serine protease inhibitor in patients with chronic hepatitis C.
Topics: 2',5'-Oligoadenylate Synthetase; Adult; Aged; Base Sequence; Chronic Disease; Female; Gabexate; Hepa | 1996 |